Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.49 |
| ▸ | RET | P07949 | 5/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | GALR2 | O43603 | 1/20 | 0.39 |
| ▸ | GALR1 | P47211 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25620162 | 0.87 | GPR119 (0.45) | GPR119RETJAK3 | |
| SCHEMBL25864343 | 0.85 | CKS1B (0.41) | RETCKS1BSKP1SKP2GALR2 | |
| SCHEMBL24091519 | 0.82 | GPR119 (0.47) | GPR119RETKCNH2JAK3EGLN2 | |
| SCHEMBL22638913 | 0.78 | GPR119 (0.59) | GPR119RETJAK3EGLN2 | |
| SCHEMBL31518426 | 0.78 | GPR119 (0.56) | GPR119KCNH2GBA1EGLN2PIK3CA | |
| SCHEMBL24091509 | 0.77 | GPR119 (0.59) | GPR119RETCKS1BSKP1SKP2 | |
| SCHEMBL24091582 | 0.76 | GPR119 (0.46) | GPR119RETJAK3 | |
| SCHEMBL30718207 | 0.75 | GPR119 (0.53) | GPR119KCNH2EGLN2PIK3CA | |
| SCHEMBL27029527 | 0.75 | GPR119 (0.53) | GPR119KCNH2EGLN2PIK3CA | |
| SCHEMBL9669980 | 0.74 | GBA1 (0.56) | GPR119CKS1BSKP1SKP2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | GPR119 1460/4885RET 36/4885CKS1B 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.